|
|
|
|
|
| |Product Pipeline |Product Portfolio   |
| Cardiovascular Diseases | Central Nervous System Disorders | Infectious Diseases | | Arthritis/Inflammation | Metabolic Diseases| Allergic Diseases | | Cancer | Genitourinary/Sexual Health | Surgery/Interventional | | Consumer Health/OTC | Animal Health | | |
| ||
| MAJOR PFIZER PRODUCTS AND SELECTED CANDIDATES IN DEVELOPMENT | ||
| Metabolic Diseases | ||
| Current Products | ||
| Diabinese (Type-2 diabetes) Glucotrol (Type-2 diabetes) Glucotrol XL (Type-2 diabetes) |
||
| Extensions / Additional Indications (last 12 months) | Under Regulatory Review | In Advanced-Stage Development |
|
Alond (zopolrestat) (for prevention of diabetic complications) droloxifene (for prevention and/or treatment of osteoporosis) inhaled insulin (novel delivery system; for diabetes) | ||
| Key: [U.S.]—U.S. only [I]—International only (in at least one country) No Key—Both U.S. and at least one other country | ||
|
|
|
| ||||
 |
 |
 |
 | |
| ||||
 |
||||
 |
||||
| Advisory Information for Investors | ||||
| Copyright © 1997, 1998 Pfizer Inc All rights reserved. | ||||
| ||||